uniQure Stock (NASDAQ:QURE)
Previous Close
$5.82
52W Range
$3.73 - $11.35
50D Avg
$5.91
200D Avg
$5.75
Market Cap
$277.84M
Avg Vol (3M)
$676.88K
Beta
0.90
Div Yield
-
QURE Company Profile
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Performance
Peer Comparison
| Ticker | Company |
|---|---|
| XFOR | X4 Pharmaceuticals, Inc. |
| KNSA | Kiniksa Pharmaceuticals, Ltd. |
| MRUS | Merus N.V. |
| LRMR | Larimar Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PHAT | Phathom Pharmaceuticals, Inc. |
| MGTX | MeiraGTx Holdings plc |
| RCKT | Rocket Pharmaceuticals, Inc. |
| RNA | Avidity Biosciences, Inc. |
| STRO | Sutro Biopharma, Inc. |
| RGNX | REGENXBIO Inc. |
| REPL | Replimune Group, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| GPCR | Structure Therapeutics Inc. |
| RYTM | Rhythm Pharmaceuticals, Inc. |
| PCVX | Vaxcyte, Inc. |
| SLDB | Solid Biosciences Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| KRTX | Karuna Therapeutics, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |